http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1786766-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2602-08 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D275-02 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-26 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D275-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-07 |
filingDate | 2005-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2010-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b9a3c4ba75bacaba6c2e3416761fde3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca42b79e7afe73030c696cb051285e8d |
publicationDate | 2010-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1786766-B1 |
titleOfInvention | Compounds which potentiate glutamate receptor and uses thereof in medicine |
abstract | Compounds of formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1 4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino; each R4, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; p is 0, 1 or 2; each R5, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; q is 0,1 or 2; R6 is -NR6aSO2R6b, -NR6aC(=O)R6b, -NR6a(C=O)N(R6c)2, -(C=O)R6d, CH2NR6aSO2R6b, -CH2NR6aC(=O)R6b, -CH2NR6a(C=O)N(R6c)2 or CH2(C=O)R6d; where R6a and each R6c, which may be the same or different, is hydrogen or C1-6alkyl; R6b and R6d are C1-6alkyl or haloC1-6alkyl; or R6a and R6b, or R6a and R6c, together with the interconnecting atoms, may form a 5- or 6-membered ring; n is 1 or 2; and R7 and R8, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed. |
priorityDate | 2004-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 808.